Cannabis Use Disorder Market to Grow via Digital Therapeutics

Cannabis Use Disorder Market to Grow via Digital Therapeutics

The Cannabis Use Disorder Market encompasses a range of therapeutic interventions, including pharmacotherapies, behavioral therapies, and emerging digital solutions designed to treat individuals exhibiting dependency on cannabis. Products under development target neurotransmitter pathways implicated in addiction, aiming to reduce withdrawal symptoms, curb cravings, and enhance patient compliance. Behavioral tools, such as cognitive-behavioral therapy modules delivered via mobile apps, offer personalized support and continuous monitoring, improving long-term abstinence rates. Key advantages of these offerings include non-invasive delivery, reduced side effects compared to traditional psychotropic drugs, and the ability to tailor interventions to individual patient profiles.

Growing awareness of Cannabis Use Disorder Market and an expanding healthcare infrastructure supportive of innovative treatment models have spurred demand for novel therapies. As regulatory bodies across North America and Europe grant accelerated approvals for digital therapeutics, stakeholders can capitalize on seamless integration with telehealth platforms. Rising investment in R&D and strategic partnerships between pharmaceutical companies and technology firms further bolster product pipelines. With a surge in clinical trials validating efficacy and safety, patient access to cutting-edge treatments is set to improve.

The cannabis use disorder market is estimated to be valued at USD 1.80 Bn in 2025 and is expected to reach USD 3.40 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.

Key Takeaways

Key players operating in the Cannabis Use Disorder Market are:

-Aelis Farma

-Indivior

-Pfizer

-Corbus Pharmaceuticals

-Zynerba Pharmaceuticals

These market companies have strengthened their position through dedicated clinical programs and licensing agreements, aiming to capture significant market share as competition intensifies.

Significant market opportunities lie in expanding digital health infrastructure and telemedicine adoption. Emerging economies in Asia-Pacific and Latin America present untapped patient pools, while reimbursement policies are increasingly favorable toward technology-enabled care. Integration of digital therapeutics with wearable sensors offers real-time monitoring of patient adherence, representing a lucrative segment for new entrants. Public–private collaborations and grants focused on addiction research further unlock avenues for innovative product launches and business growth.

The adoption of Digital Therapeutics represents a transformative technological advancement in Cannabis Use Disorder treatment. By leveraging machine-learning algorithms and patient data analytics, developers can refine behavioral interventions and predict relapse risk with high accuracy. Such technology-driven solutions align with broader industry trends toward personalized medicine, driving sustainable market growth and reinforcing the market’s appeal to investors seeking scalable, data-backed therapies.

Market Drivers

One of the primary market drivers for the Cannabis Use Disorder Market is the escalating prevalence of cannabis dependence worldwide, coupled with a growing recognition of its neuropsychiatric impact. As cannabis use rates climb among adolescents and adults, healthcare systems face mounting pressure to provide effective, evidence-based treatment options. This rising burden directly fuels investment into research and development of novel therapeutics, including both pharmacological agents and digital platforms. Heightened public awareness and destigmatization of substance use disorders further encourage individuals to seek help, expanding the treated population and driving market growth. Moreover, advances in digital infrastructure and telehealth services streamline patient access to specialized care, reducing geographic barriers and lowering treatment costs. Health authorities in key markets have issued guidelines endorsing integrated care models, which combine medication with digital behavioral support, thereby promoting broader adoption of innovative interventions. These factors collectively reinforce the market’s positive trajectory, ensuring sustained expansion in line with projected market size and delivering meaningful clinical outcomes for patients.

Current Challenges in the Cannabis Use Disorder Market

The Cannabis Use Disorder Market is navigating several complex market challenges that stem from regulatory uncertainty, social stigma, and fragmented treatment protocols. Despite growing interest in therapeutic options, inconsistent legislation across regions impedes cohesive market growth and complicates market forecast accuracy. Healthcare providers often lack standardized guidelines for diagnosing and managing cannabis dependence, which hinders the adoption of new pharmacological and behavioral therapies. Funding limitations for clinical trials further restrict the development of innovative treatments and reduce overall market insights into long-term efficacy. Patient reluctance, driven by the stigma associated with substance use disorders, can also diminish market opportunities by limiting enrollment in research studies. Meanwhile, payers and insurers struggle to classify treatments for cannabis use disorder, creating reimbursement barriers that suppress investment by market companies. Finally, a shortage of specialized training among practitioners dampens market dynamics, as professionals may be ill-equipped to implement comprehensive programs for prevention, intervention, and relapse management. Addressing these interrelated obstacles is essential to unlocking future market growth and delivering effective care models for individuals affected by cannabis dependency.

SWOT Analysis

Content
Strength: Rapidly evolving clinical research and a growing emphasis on mental health treatment have created robust market dynamics for cannabis use disorder therapies. Enhanced collaboration between academic institutions and private sector market players accelerates innovation and clinical validation.
Weakness: Regulatory ambiguity and varying legal status across jurisdictions pose two significant weaknesses. First, inconsistent legislation limits multicenter trials. Second, stigma around substance abuse discourages both patient participation and prescriber adoption.
Opportunity: Two primary opportunities exist. The integration of telemedicine and digital therapeutics can expand patient access and support early intervention, creating new market segments. Additionally, partnerships with mental health organizations can enhance patient education, driving market insights and uptake.
Threats: First, the emergence of alternative addiction treatments targeting broader substance use could divert investment and attention away from cannabis-specific therapies. Second, potential shifts in healthcare policy or funding priorities may reduce research grants and reimbursement support, stalling market growth strategies.

Geographical Regions

Value Concentration
North America remains the dominant region in terms of market share and revenue for cannabis use disorder treatment, owing to well-established healthcare infrastructure and supportive research funding. The United States leads with strong academic-industry partnerships and a high density of specialized rehabilitation centers. Western Europe follows closely, with countries such as Germany and the UK investing in clinical trials and public awareness campaigns. Adoption of evidence-based protocols in these markets drives premium pricing and encourages the entry of innovative therapies. Collectively, these regions account for the majority of global market revenue and benefit from comprehensive insurance coverage and robust post-marketing surveillance that inform ongoing market analysis.

Fastest-Growing Region

The Asia Pacific region is poised to exhibit the fastest market growth, driven by expanding healthcare access, rising awareness of mental health issues, and increasing government initiatives targeting substance abuse. China and India are investing in large-scale screening programs and pilot intervention projects, generating valuable epidemiological data. Southeast Asian nations, notably Thailand and Malaysia, have begun liberalizing medical cannabis policies and supporting clinical research, creating fertile ground for new market segments. Enhanced digital health adoption and telepsychiatry solutions further fuel rapid uptake, offering scalable treatment models that overcome geographical barriers. As regulatory frameworks mature and public education campaigns intensify, the Asia Pacific market is expected to outpace other regions in percentage growth over the next several years.

‣ Get this Report in Japanese Language: 大麻使用障害市場

‣ Get this Report in Korean Language: 대마사용장애시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)